85. 特発性間質性肺炎 Idiopathic interstitial pneumonia Clinical trials / Disease details
臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05497284 (ClinicalTrials.gov) | November 10, 2022 | 5/8/2022 | To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF | A Participant- and Investigator-blinded, Randomized, Placebo-controlled, Multicenter, Platform Study to Investigate Efficacy, Safety, and Tolerability of Various Single Treatments in Participants With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Drug: LTP001;Drug: Placebo;Drug: Standard of Care (SoC) | Novartis Pharmaceuticals | NULL | Recruiting | 40 Years | N/A | All | 94 | Phase 2 | United States;Argentina;Australia |